{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:59:58Z","timestamp":1785517198563,"version":"3.56.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004913","name":"Universit\u00e0 degli Studi di Palermo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004913","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infection"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Carbapenem-resistant\n                    <jats:italic>Acinetobacter baumannii<\/jats:italic>\n                    (CRAB) represents a critical therapeutic challenge due to limited effective treatment options and high associated mortality. Fosfomycin has been increasingly investigated as an adjunctive agent in combination regimens, despite its intrinsically reduced activity against\n                    <jats:italic>A. baumannii<\/jats:italic>\n                    . This narrative review summarizes current in vitro, in vivo, and clinical evidence on fosfomycin-containing therapies for CRAB infections. A total of 48 studies were included, encompassing in vitro (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200927), animal (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u20092), and clinical investigations (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200920). In one case, both in vitro and clinical data were reported. In vitro data suggest that fosfomycin may exhibit synergistic or additive activity when combined with several anti-CRAB agents, most consistently with sulbactam, imipenem, and colistin, although results are highly heterogeneous and method-dependent. Although limited, in vivo studies indicate improved bacterial clearance with fosfomycin-based combinations, particularly in pneumonia models. Clinical evidence remains largely observational and non-randomized, frequently involving critically ill patients receiving multiple combination therapies. While some multicenter studies, particularly from Italian cohorts, report improved clinical outcomes and survival associated with fosfomycin-containing regimens, especially in combination with cefiderocol, other studies do not confirm a clear benefit. Clinical trials have mainly demonstrated improvements in microbiological response and early infection control, without consistent effects on mortality. Overall, current evidence suggests that fosfomycin may provide additional benefit when incorporated into selected combination regimens for CRAB infections, although its independent contribution remains uncertain. Among the evaluated regimens, cefiderocol-fosfomycin combinations currently appear to be supported by the most encouraging observational clinical evidence, particularly regarding early clinical response and microbiological control.\n                  <\/jats:p>","DOI":"10.1007\/s15010-026-02895-8","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T13:55:55Z","timestamp":1785160555000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Fosfomycin as an adjunctive agent against carbapenem-resistant Acinetobacter baumannii: an updated narrative review"],"prefix":"10.1007","author":[{"given":"Luca","family":"Pipit\u00f2","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara Vincenza","family":"Mazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1992-1796","authenticated-orcid":false,"given":"Antonio","family":"Cascio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"2895_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25136814","volume":"25","author":"A Marino","year":"2024","unstructured":"Marino A, Augello E, Stracquadanio S, Bellanca CM, Cosentino F, Spampinato S, et al. Unveiling the secrets of Acinetobacter baumannii: resistance, current treatments, and future innovations. Int J Mol Sci. 2024;25:6814. https:\/\/doi.org\/10.3390\/ijms25136814.","journal-title":"Int J Mol Sci"},{"key":"2895_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14020186","volume":"14","author":"L Pipit\u00f2","year":"2025","unstructured":"Pipit\u00f2 L, Rubino R, D\u2019Agati G, Bono E, Mazzola CV, Urso S, et al. Antimicrobial resistance in ESKAPE pathogens: a retrospective epidemiological study at the University Hospital of Palermo, Italy. Antibiotics (Basel). 2025;14:186. https:\/\/doi.org\/10.3390\/antibiotics14020186.","journal-title":"Antibiotics (Basel)"},{"key":"2895_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics14050464","volume":"14","author":"L Pipit\u00f2","year":"2025","unstructured":"Pipit\u00f2 L, Bono E, Mazzola CV, Rubino R, Anastasia A, Distefano SA, et al. Outcome of bloodstream infections caused by antibiotic-resistant bacteria: a 7-year retrospective study at the University Hospital of Palermo, Italy. Antibiotics (Basel). 2025;14:464. https:\/\/doi.org\/10.3390\/antibiotics14050464.","journal-title":"Antibiotics (Basel)"},{"key":"2895_CR4","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.idc.2025.12.001","volume":"40","author":"A Cascio","year":"2026","unstructured":"Cascio A, Pipit\u00f2 L, Paterson DL. How to Treat Carbapenem-Resistant Acinetobacter baumannii Infections. Infect Dis Clin N Am. 2026;40:23\u201339. https:\/\/doi.org\/10.1016\/j.idc.2025.12.001.","journal-title":"Infect Dis Clin N Am"},{"key":"2895_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","volume":"48","author":"HW Boucher","year":"2009","unstructured":"Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, Scheld M, Spellberg B, Bartlett J. Bad Bugs, No Drugs: No ESKAPE! An Update from the Infectious Diseases Society of America. CLIN INFECT DIS. 2009;48:1\u201312. https:\/\/doi.org\/10.1086\/595011.","journal-title":"CLIN INFECT DIS"},{"key":"2895_CR6","unstructured":"WHO bacterial priority pathogens list. 2024: Bacterial pathogens of public health importance to guide research, development and strategies to prevent and control antimicrobial resistance Accessed on 4 May 2026. https:\/\/www.who.int\/publications\/i\/item\/9789240093461. n.d."},{"key":"2895_CR7","unstructured":"Dijkmans AC, Zacar\u00edas NVO, Burggraaf J, Mouton JW, Wilms EB. Fosfomycin: Pharmacological, Clinical and Future Perspectives n.d."},{"key":"2895_CR8","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40121-025-01125-2","volume":"14","author":"K-F Bodmann","year":"2025","unstructured":"Bodmann K-F, Hagel S, Oliva A, Kluge S, Mularoni A, Galfo V, et al. Real-world use, effectiveness, and safety of intravenous Fosfomycin: the FORTRESS study. Infect Dis Ther. 2025;14:765\u201391. https:\/\/doi.org\/10.1007\/s40121-025-01125-2.","journal-title":"Infect Dis Ther"},{"key":"2895_CR9","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1046\/j.1469-0691.2000.00149.x","volume":"6","author":"Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents","year":"2000","unstructured":"Terminology relating to methods for the determination of susceptibility of bacteria to antimicrobial agents. Clin Microbiol Infect. 2000;6:503\u20138. https:\/\/doi.org\/10.1046\/j.1469-0691.2000.00149.x.","journal-title":"Clin Microbiol Infect"},{"key":"2895_CR10","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1128\/CMR.00068-15","volume":"29","author":"ME Falagas","year":"2016","unstructured":"Falagas ME, Vouloumanou EK, Samonis G, Vardakas KZ. Fosfomycin. Clin Microbiol Rev. 2016;29:321\u201347. https:\/\/doi.org\/10.1128\/CMR.00068-15.","journal-title":"Clin Microbiol Rev"},{"key":"2895_CR11","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1093\/jac\/dkl464","volume":"59","author":"M Zeitlinger","year":"2006","unstructured":"Zeitlinger M, Marsik C, Steiner I, Sauermann R, Seir K, Jilma B, et al. Immunomodulatory effects of fosfomycin in an endotoxin model in human blood. J Antimicrob Chemother. 2006;59:219\u201323. https:\/\/doi.org\/10.1093\/jac\/dkl464.","journal-title":"J Antimicrob Chemother"},{"key":"2895_CR12","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1128\/AAC.43.3.697","volume":"43","author":"T Matsumoto","year":"1999","unstructured":"Matsumoto T, Tateda K, Miyazaki S, Furuya N, Ohno A, Ishii Y, et al. Fosfomycin alters lipopolysaccharide-induced inflammatory cytokine production in mice. Antimicrob Agents Chemother. 1999;43:697\u20138. https:\/\/doi.org\/10.1128\/AAC.43.3.697.","journal-title":"Antimicrob Agents Chemother"},{"key":"2895_CR13","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1093\/jac\/38.6.1107","volume":"38","author":"L Martinez-Martinez","year":"1996","unstructured":"Martinez-Martinez L, Rodriguez G, Pascual A, Isabel Su\u00e1rez A, Perea EJ. In-vitro activity of antimicrobial agent combinations against multiresistant Acinetobacter baumannii. J Antimicrob Chemother. 1996;38:1107\u20138. https:\/\/doi.org\/10.1093\/jac\/38.6.1107.","journal-title":"J Antimicrob Chemother"},{"key":"2895_CR14","unstructured":"Santimaleeworagun W, Wongpoowarak P, Chayakul P, Pattharachayakul S, Tansakul P, Garey KW. In vitro activity of colistin or sulbactam in combination with fosfomycin or imipenem against clinical isolates of carbapenem-resistant Acinetobacter baumannii producing OXA-23 carbapenemases. 2011."},{"key":"2895_CR15","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.3892\/etm.2013.1039","volume":"5","author":"Y Zhang","year":"2013","unstructured":"Zhang Y, Chen F, Sun E, Ma R, Qu C, Ma L. In vitro antibacterial activity of combinations of fosfomycin, minocycline and polymyxin B on pan-drug-resistant Acinetobacter baumannii. Exp Ther Med. 2013;5:1737\u20139. https:\/\/doi.org\/10.3892\/etm.2013.1039.","journal-title":"Exp Ther Med"},{"key":"2895_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0151270","volume":"11","author":"GC Leite","year":"2016","unstructured":"Leite GC, Oliveira MS, Perdig\u00e3o-Neto LV, Rocha CKD, Guimar\u00e3es T, Rizek C, et al. Antimicrobial combinations against pan-resistant Acinetobacter baumannii isolates with different resistance mechanisms. PLoS One. 2016;11:e0151270. https:\/\/doi.org\/10.1371\/journal.pone.0151270.","journal-title":"PLoS One"},{"key":"2895_CR17","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.ijantimicag.2016.02.007","volume":"47","author":"TC Menegucci","year":"2016","unstructured":"Menegucci TC, Albiero J, Migliorini LB, Alves JLB, Viana GF, Mazucheli J, et al. Strategies for the treatment of polymyxin B-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents. 2016;47:380\u20135. https:\/\/doi.org\/10.1016\/j.ijantimicag.2016.02.007.","journal-title":"Int J Antimicrob Agents"},{"key":"2895_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1179\/1973947815Y.0000000030","volume":"28","author":"W Wei","year":"2016","unstructured":"Wei W, Yang H, Liu Y, Ye Y, Li J. In vitro synergy of colistin combinations against extensively drug-resistant Acinetobacter baumannii producing OXA-23 carbapenemase. J Chemother. 2016;28:159\u201363. https:\/\/doi.org\/10.1179\/1973947815Y.0000000030.","journal-title":"J Chemother"},{"key":"2895_CR19","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1016\/j.jiph.2018.07.006","volume":"11","author":"W Zhu","year":"2018","unstructured":"Zhu W, Wang Y, Cao W, Cao S, Zhang J. In vitro evaluation of antimicrobial combinations against imipenem-resistant Acinetobacter baumannii of different MICs. J Infect Public Health. 2018;11:856\u201360. https:\/\/doi.org\/10.1016\/j.jiph.2018.07.006.","journal-title":"J Infect Public Health"},{"key":"2895_CR20","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.diagmicrobio.2018.01.008","volume":"91","author":"U Singkham-in","year":"2018","unstructured":"Singkham-in U, Chatsuwan T. In vitro activities of carbapenems in combination with amikacin, colistin, or fosfomycin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Diagn Microbiol Infect Dis. 2018;91:169\u201374. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2018.01.008.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2895_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2018\/3893492","volume":"2018","author":"S Leelasupasri","year":"2018","unstructured":"Leelasupasri S, Santimaleeworagun W, Jitwasinkul T. Antimicrobial susceptibility among colistin, sulbactam, and fosfomycin and a synergism study of colistin in combination with sulbactam or fosfomycin against clinical isolates of carbapenem-resistant Acinetobacter baumannii. J Pathog. 2018;2018:1\u20135. https:\/\/doi.org\/10.1155\/2018\/3893492.","journal-title":"J Pathog"},{"key":"2895_CR22","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01989-18","volume":"63","author":"X Bian","year":"2019","unstructured":"Bian X, Liu X, Chen Y, Chen D, Li J, Zhang J. Dose optimization of colistin combinations against carbapenem-resistant Acinetobacter baumannii from patients with hospital-acquired pneumonia in China by using an in vitro pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother. 2019;63:e01989-18. https:\/\/doi.org\/10.1128\/AAC.01989-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"2895_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02549-18","volume":"63","author":"RK Flamm","year":"2019","unstructured":"Flamm RK, Rhomberg PR, Lindley JM, Sweeney K, Ellis-Grosse EJ, Shortridge D. Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents tested against gram-negative bacterial strains by using time-kill curves. Antimicrob Agents Chemother. 2019;63:e02549-18. https:\/\/doi.org\/10.1128\/AAC.02549-18.","journal-title":"Antimicrob Agents Chemother"},{"key":"2895_CR24","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02472-20","volume":"65","author":"S Mohd Sazlly Lim","year":"2021","unstructured":"Mohd Sazlly Lim S, Heffernan AJ, Roberts JA, Sime FB. Semimechanistic pharmacokinetic\/pharmacodynamic modeling of fosfomycin and sulbactam combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2021;65:e02472-20. https:\/\/doi.org\/10.1128\/AAC.02472-20.","journal-title":"Antimicrob Agents Chemother"},{"key":"2895_CR25","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1038\/s41598-021-04303-7","volume":"12","author":"U Singkham-in","year":"2022","unstructured":"Singkham-in U, Chatsuwan T. Synergism of imipenem with fosfomycin associated with the active cell wall recycling and heteroresistance in Acinetobacter calcoaceticus-baumannii complex. Sci Rep. 2022;12:230. https:\/\/doi.org\/10.1038\/s41598-021-04303-7.","journal-title":"Sci Rep"},{"key":"2895_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2022.115712","volume":"103","author":"C Xu","year":"2022","unstructured":"Xu C, Chen T, Zhang S, Zhou C, Liao W, Fang R, et al. In vitro activity of imipenem-relebactam alone and in combination with fosfomycin against carbapenem-resistant gram-negative pathogens. Diagn Microbiol Infect Dis. 2022;103:115712. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2022.115712.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2895_CR27","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1093\/jac\/dkac142","volume":"77","author":"SR Boncompagni","year":"2022","unstructured":"Boncompagni SR, Micieli M, Di Maggio T, Aiezza N, Antonelli A, Giani T, et al. Activity of fosfomycin\/colistin combinations against planktonic and biofilm Gram-negative pathogens. J Antimicrob Chemother. 2022;77:2199\u2013208. https:\/\/doi.org\/10.1093\/jac\/dkac142.","journal-title":"J Antimicrob Chemother"},{"key":"2895_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics11111578","volume":"11","author":"S Mohd Sazlly Lim","year":"2022","unstructured":"Mohd Sazlly Lim S, Heffernan A, Naicker S, Wallis S, Roberts JA, Sime FB. Evaluation of fosfomycin-sulbactam combination therapy against carbapenem-resistant Acinetobacter baumannii isolates in a hollow-fibre infection model. Antibiotics (Basel). 2022;11:1578. https:\/\/doi.org\/10.3390\/antibiotics11111578.","journal-title":"Antibiotics (Basel)"},{"key":"2895_CR29","doi-asserted-by":"publisher","first-page":"365","DOI":"10.5578\/mb.20239930","volume":"57","author":"R Adaleti","year":"2023","unstructured":"Adaleti R, Nakipo\u011flu Y, Ar\u0131c\u0131 N, Kansak N, \u00c7al\u0131k \u015e, \u015eenbayrak S, et al. Evaluation of in vitro efficacy of meropenem\/colistin and meropenem\/fosfomycin combinations on multidrug resistant Gram-negative bacilli. Mikrobiyol Bul. 2023;57:365\u201377. https:\/\/doi.org\/10.5578\/mb.20239930.","journal-title":"Mikrobiyol Bul"},{"key":"2895_CR30","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12050858","volume":"12","author":"M Palombo","year":"2023","unstructured":"Palombo M, Bovo F, Amadesi S, Gaibani P. Synergistic activity of cefiderocol in combination with piperacillin-tazobactam, fosfomycin, ampicillin-sulbactam, imipenem-relebactam and ceftazidime-avibactam against carbapenem-resistant Gram-negative bacteria. Antibiotics (Basel). 2023;12:858. https:\/\/doi.org\/10.3390\/antibiotics12050858.","journal-title":"Antibiotics (Basel)"},{"key":"2895_CR31","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11061409","volume":"11","author":"MA Quraini","year":"2023","unstructured":"Quraini MA, Jabri ZA, Sami H, Mahindroo J, Taneja N, Muharrmi ZA, et al. Exploring synergistic combinations in extended and pan-drug resistant (XDR and PDR) whole genome sequenced Acinetobacter baumannii. Microorganisms. 2023;11:1409. https:\/\/doi.org\/10.3390\/microorganisms11061409.","journal-title":"Microorganisms"},{"key":"2895_CR32","doi-asserted-by":"publisher","DOI":"10.1186\/s40001-024-01885-6","volume":"29","author":"T M\u00fcderris","year":"2024","unstructured":"M\u00fcderris T, Dursun Manyasl\u0131 G, Sezak N, Kaya S, Demirdal T, G\u00fcl Yurtsever S. In-vitro evaluation of different antimicrobial combinations with and without colistin against carbapenem-resistant Acinetobacter baumannii clinical isolates. Eur J Med Res. 2024;29:331. https:\/\/doi.org\/10.1186\/s40001-024-01885-6.","journal-title":"Eur J Med Res"},{"key":"2895_CR33","doi-asserted-by":"publisher","first-page":"630","DOI":"10.3390\/antibiotics14070630","volume":"14","author":"P Jaglal","year":"2025","unstructured":"Jaglal P, Velaphi SC, Menezes CN, Swe Swe-Han K. In vitro evaluation of antimicrobial synergy against multidrug-resistant gram-negative paediatric bloodstream pathogens in South Africa. Antibiotics. 2025;14:630. https:\/\/doi.org\/10.3390\/antibiotics14070630.","journal-title":"Antibiotics"},{"key":"2895_CR34","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.01379-25","volume":"13","author":"A Jitmuang","year":"2025","unstructured":"Jitmuang A, Tiengrim S, Thamlikitkul V, Koomanachai P. In vitro activity of sulbactam in combination with other antimicrobial agents against extensively drug-resistant Acinetobacter baumannii. Microbiol Spectr. 2025;13:e01379-25. https:\/\/doi.org\/10.1128\/spectrum.01379-25.","journal-title":"Microbiol Spectr"},{"key":"2895_CR35","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-025-05398-w","author":"G Zocche","year":"2026","unstructured":"Zocche G, Lewis RE, Bianco G, Tascini C, Gaibani P. In vitro interactions of sulbactam\/durlobactam in combination with meropenem, ceftazidime\/avibactam, piperacillin\/tazobactam, cefiderocol and fosfomycin against carbapenem-resistant Acinetobacter baumannii (CRAB) clinical isolates. Eur J Clin Microbiol Infect Dis. 2026. https:\/\/doi.org\/10.1007\/s10096-025-05398-w.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2895_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11092352","volume":"11","author":"B Grygorcewicz","year":"2023","unstructured":"Grygorcewicz B, Gli\u017aniewicz M, Olszewska P, Mi\u0142ek D, Czajkowski A, Serwin N, et al. Response surface methodology application for bacteriophage\u2013antibiotic antibiofilm activity optimization. Microorganisms. 2023;11:2352. https:\/\/doi.org\/10.3390\/microorganisms11092352.","journal-title":"Microorganisms"},{"key":"2895_CR37","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00203-022-03020-7","volume":"204","author":"B Grygorcewicz","year":"2022","unstructured":"Grygorcewicz B, Roszak M, Rakoczy R, Augustyniak A, Konopacki M, Jab\u0142o\u0144ska J, Serwin N, Cecerska-Hery\u0107 E, Kordas M, Galant K, Do\u0142\u0119gowska B. PhageScore-based analysis of Acinetobacter baumannii infecting phages antibiotic interaction in liquid medium. Arch Microbiol. 2022;204:421. https:\/\/doi.org\/10.1007\/s00203-022-03020-7.","journal-title":"Arch Microbiol"},{"issue":"5","key":"2895_CR38","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1021\/acsinfecdis.4c00077","volume":"10","author":"M Saini","year":"2024","unstructured":"Saini M, Gaurav A, Hussain A, Pathania R. Small molecule IITR08367 potentiates antibacterial efficacy of fosfomycin against Acinetobacter baumannii by efflux pump inhibition. ACS Infect Dis. 2024;10(5):1711\u201324. https:\/\/doi.org\/10.1021\/acsinfecdis.4c00077.","journal-title":"ACS Infect Dis"},{"key":"2895_CR39","doi-asserted-by":"publisher","first-page":"45914","DOI":"10.1021\/acsomega.3c06719","volume":"8","author":"R Zhu","year":"2023","unstructured":"Zhu R, Yin Z, Liu N, Wang Z, Zhang H, Li J, et al. Polymyxin B-modified fosfomycin liposomes target Gram-negative bacteria and exert synergistic antibacterial effect. ACS Omega. 2023;8:45914\u201323. https:\/\/doi.org\/10.1021\/acsomega.3c06719.","journal-title":"ACS Omega"},{"key":"2895_CR40","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0157757","volume":"11","author":"B Fan","year":"2016","unstructured":"Fan B, Guan J, Wang X, Cong Y. Activity of colistin in combination with meropenem, tigecycline, fosfomycin, fusidic acid, rifampin or sulbactam against extensively drug-resistant Acinetobacter baumannii in a murine thigh-infection model. PLoS One. 2016;11:e0157757. https:\/\/doi.org\/10.1371\/journal.pone.0157757.","journal-title":"PLoS One"},{"key":"2895_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53714-0","volume":"9","author":"NS Ku","year":"2019","unstructured":"Ku NS, Lee S-H, Lim Y-S, Choi H, Ahn JY, Jeong SJ, et al. In vivo efficacy of combination of colistin with fosfomycin or minocycline in a mouse model of multidrug-resistant Acinetobacter baumannii pneumonia. Sci Rep. 2019;9:17127. https:\/\/doi.org\/10.1038\/s41598-019-53714-0.","journal-title":"Sci Rep"},{"key":"2895_CR42","doi-asserted-by":"publisher","first-page":"5598","DOI":"10.1128\/AAC.02435-13","volume":"58","author":"R Sirijatuphat","year":"2014","unstructured":"Sirijatuphat R, Thamlikitkul V. Preliminary study of colistin versus colistin plus fosfomycin for treatment of carbapenem-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58:5598\u2013601. https:\/\/doi.org\/10.1128\/AAC.02435-13.","journal-title":"Antimicrob Agents Chemother"},{"key":"2895_CR43","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1111\/crj.13594","volume":"17","author":"A Hakamifard","year":"2023","unstructured":"Hakamifard A, Torfeh Esfahani AA, Homayouni A, Khorvash F, Ataei B, Abbasi S. Comparing inhaled colistin with inhaled fosfomycin\/tobramycin as an adjunctive treatment for ventilator-associated pneumonia: An open\u2010label randomized controlled trial. Clin Respiratory J. 2023;17:295\u2013302. https:\/\/doi.org\/10.1111\/crj.13594.","journal-title":"Clin Respiratory J"},{"key":"2895_CR44","doi-asserted-by":"publisher","DOI":"10.1002\/hsr2.71670","volume":"8","author":"A Hakamifard","year":"2025","unstructured":"Hakamifard A, Mohammadi MR, Homayouni A, Khorvash F, Abbasi S, Ataei B, et al. Evaluation of inhaled colistin\/fosfomycin as an adjunctive treatment for ventilator-associated pneumonia: A preliminary study. Health Sci Rep. 2025;8:e71670. https:\/\/doi.org\/10.1002\/hsr2.71670.","journal-title":"Health Sci Rep"},{"key":"2895_CR45","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s40121-020-00357-8","volume":"10","author":"A Russo","year":"2021","unstructured":"Russo A, Bassetti M, Bellelli V, Bianchi L, Marincola Cattaneo F, Mazzocchetti S, et al. Efficacy of a fosfomycin-containing regimen for treatment of severe pneumonia caused by multidrug-resistant Acinetobacter baumannii: a prospective, observational study. Infect Dis Ther. 2021;10:187\u2013200. https:\/\/doi.org\/10.1007\/s40121-020-00357-8.","journal-title":"Infect Dis Ther"},{"key":"2895_CR46","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.910031","volume":"9","author":"E Casarotta","year":"2022","unstructured":"Casarotta E, Bottari E, Vannicola S, Giorgetti R, Domizi R, Carsetti A, et al. Antibiotic treatment of Acinetobacter baumannii superinfection in patients with SARS-CoV-2 infection admitted to intensive care unit: an observational retrospective study. Front Med. 2022;9:910031. https:\/\/doi.org\/10.3389\/fmed.2022.910031.","journal-title":"Front Med"},{"key":"2895_CR47","doi-asserted-by":"publisher","first-page":"699","DOI":"10.3947\/ic.2022.0098","volume":"54","author":"A Thampithak","year":"2022","unstructured":"Thampithak A, Chaisiri K, Siangsuebchart O, Phengjaturat K, Aonjumras W, Hemapanpairoa J. Prescription pattern of intravenous fosfomycin in a provincial hospital in Thailand. Infect Chemother. 2022;54:699. https:\/\/doi.org\/10.3947\/ic.2022.0098.","journal-title":"Infect Chemother"},{"key":"2895_CR48","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms11040984","volume":"11","author":"M Mazzitelli","year":"2023","unstructured":"Mazzitelli M, Gregori D, Sasset L, Trevenzoli M, Scaglione V, Lo Menzo S, et al. Cefiderocol-based versus colistin-based regimens for severe carbapenem-resistant Acinetobacter baumannii infections: a propensity score-weighted, retrospective cohort study during the first two years of the COVID-19 pandemic. Microorganisms. 2023;11:984. https:\/\/doi.org\/10.3390\/microorganisms11040984.","journal-title":"Microorganisms"},{"key":"2895_CR49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106825","volume":"62","author":"A Russo","year":"2023","unstructured":"Russo A, Bruni A, Gull\u00ec S, Borrazzo C, Quirino A, Lionello R, et al. Efficacy of cefiderocol- vs colistin-containing regimen for treatment of bacteraemic ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii in patients with COVID-19. Int J Antimicrob Agents. 2023;62:106825. https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106825.","journal-title":"Int J Antimicrob Agents"},{"key":"2895_CR50","doi-asserted-by":"publisher","first-page":"107190","DOI":"10.1016\/j.ijantimicag.2024.107190","volume":"64","author":"A Russo","year":"2024","unstructured":"Russo A, Gull\u00ec SP, D\u2019Avino A, Borrazzo C, Carannante N, Dezza FC, Covino S, Polistina G, Fiorentino G, Trecarichi EM, Mastroianni CM, Torti C, Oliva A. Intravenous fosfomycin for treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii: A multi-centre clinical experience. Int J Antimicrob Agents. 2024;64:107190. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107190.","journal-title":"Int J Antimicrob Agents"},{"key":"2895_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2024.107365","volume":"64","author":"A Oliva","year":"2024","unstructured":"Oliva A, Curtolo A, Falletta A, Sacco F, Lancellotti F, Carnevalini M, et al. Efficacy of fosfomycin-containing regimens in treating severe infections caused by KPC-producing Klebsiella pneumoniae and carbapenem-resistant Acinetobacter baumannii in critically ill patients. Int J Antimicrob Agents. 2024;64:107365. https:\/\/doi.org\/10.1016\/j.ijantimicag.2024.107365.","journal-title":"Int J Antimicrob Agents"},{"key":"2895_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2026.106742","volume":"92","author":"A Russo","year":"2026","unstructured":"Russo A, Gull\u00ec SP, Vena A, Spadafora L, Bernardi M, Corcione S, et al. Predictors of mortality and therapeutic efficacy in carbapenem-resistant Acinetobacter baumannii bacteremia. J Infect. 2026;92:106742. https:\/\/doi.org\/10.1016\/j.jinf.2026.106742.","journal-title":"J Infect"},{"key":"2895_CR53","doi-asserted-by":"publisher","first-page":"652","DOI":"10.3390\/antibiotics10060652","volume":"10","author":"DF Bavaro","year":"2021","unstructured":"Bavaro DF, Belati A, Diella L, Stufano M, Romanelli F, Scalone L, Stolfa S, Ronga L, Maurmo L, Dell\u2019Aera M, Mosca A, Dalfino L, Grasso S, Saracino A. Cefiderocol-based combination therapy for difficult-to-treat gram-negative severe infections: Real-life case series and future perspectives. Antibiotics. 2021;10:652. https:\/\/doi.org\/10.3390\/antibiotics10060652.","journal-title":"Antibiotics"},{"key":"2895_CR54","doi-asserted-by":"publisher","DOI":"10.3390\/antibiotics12010049","volume":"12","author":"A Marino","year":"2022","unstructured":"Marino A, Stracquadanio S, Campanella E, Munaf\u00f2 A, Gussio M, Ceccarelli M, et al. Intravenous fosfomycin: a potential good partner for cefiderocol. Clinical experience and considerations. Antibiotics (Basel, Switzerland). 2022;12:49. https:\/\/doi.org\/10.3390\/antibiotics12010049.","journal-title":"Antibiotics (Basel, Switzerland)"},{"key":"2895_CR55","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens12020286","volume":"12","author":"SF Assimakopoulos","year":"2023","unstructured":"Assimakopoulos SF, Karamouzos V, Eleftheriotis G, Lagadinou M, Bartzavali C, Kolonitsiou F, et al. Efficacy of fosfomycin-containing regimens for treatment of bacteremia due to pan-drug resistant Acinetobacter baumannii in critically ill patients: A case series study. Pathogens. 2023;12:286. https:\/\/doi.org\/10.3390\/pathogens12020286.","journal-title":"Pathogens"},{"key":"2895_CR56","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1007\/s10156-012-0404-9","volume":"18","author":"G Mellon","year":"2012","unstructured":"Mellon G, Picard B, Jaur\u00e9guy F, Clec\u2019h C, Cohen Y, Picard B, et al. Postsurgical meningitis due to multiresistant Acinetobacter baumannii successfully treated with high doses of ampicillin\/sulbactam combined with rifampicin and fosfomycin. J Infect Chemother. 2012;18:958\u201360. https:\/\/doi.org\/10.1007\/s10156-012-0404-9.","journal-title":"J Infect Chemother"},{"key":"2895_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-018-0299-0","volume":"17","author":"T Kerz","year":"2018","unstructured":"Kerz T, Von Loewenich FD, Roberts J, Neulen A, Ringel F. Cerebrospinal fluid penetration of very high-dose meropenem: A case report. Ann Clin Microbiol Antimicrob. 2018;17:47. https:\/\/doi.org\/10.1186\/s12941-018-0299-0.","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"2895_CR58","doi-asserted-by":"publisher","first-page":"408","DOI":"10.3855\/jidc.11842","volume":"14","author":"MR Aykota","year":"2020","unstructured":"Aykota MR, Sari T, Yilmaz S. Successful treatment of extreme drug resistant Acinetobacter baumannii infection following a liver transplant. J Infect Dev Ctries. 2020;14:408\u201310. https:\/\/doi.org\/10.3855\/jidc.11842.","journal-title":"J Infect Dev Ctries"},{"key":"2895_CR59","doi-asserted-by":"publisher","unstructured":"Pallotto C, Benvenuto MC, Francisci D. Shoulder prosthetic joint infection due to Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii treated with ciprofloxacin, minocycline and continuous infusion fosfomycin as OPAT regimen: A case report. JAC Antimicrob Resist. 2025;7(3):dlaf087. https:\/\/doi.org\/10.1093\/jacamr\/dlaf087. n.d.","DOI":"10.1093\/jacamr\/dlaf087"},{"key":"2895_CR60","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1716306","volume":"12","author":"J Lin","year":"2025","unstructured":"Lin J, Dai G, Zhang L, Xu P, Zhao P, Zhou Y, et al. Case report: bacteriophage-antibiotic therapy for extensively drug-resistant Acinetobacter baumannii in critically ill patient with respiratory infection. Front Med. 2025;12:1716306. https:\/\/doi.org\/10.3389\/fmed.2025.1716306.","journal-title":"Front Med"},{"key":"2895_CR61","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-90709-2","volume":"11","author":"NH Fedrigo","year":"2021","unstructured":"Fedrigo NH, Shinohara DR, Mazucheli J, Nishiyama SAB, Carrara-Marroni FE, Martins FS, et al. Pharmacodynamic evaluation of suppression of in vitro resistance in Acinetobacter baumannii strains using polymyxin B-based combination therapy. Sci Rep. 2021;11:11339. https:\/\/doi.org\/10.1038\/s41598-021-90709-2.","journal-title":"Sci Rep"},{"key":"2895_CR62","doi-asserted-by":"publisher","first-page":"3714","DOI":"10.1128\/AAC.02780-13","volume":"58","author":"AB Montgomery","year":"2014","unstructured":"Montgomery AB, Rhomberg PR, Abuan T, Walters K-A, Flamm RK. Potentiation effects of amikacin and fosfomycin against selected amikacin-nonsusceptible gram-negative respiratory tract pathogens. Antimicrob Agents Chemother. 2014;58:3714\u20139. https:\/\/doi.org\/10.1128\/AAC.02780-13.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02895-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s15010-026-02895-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s15010-026-02895-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T16:05:01Z","timestamp":1785513901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s15010-026-02895-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":62,"alternative-id":["2895"],"URL":"https:\/\/doi.org\/10.1007\/s15010-026-02895-8","relation":{},"ISSN":["0300-8126","1439-0973"],"issn-type":[{"value":"0300-8126","type":"print"},{"value":"1439-0973","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"20 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}